There's something about ILK

International Journal of Radiation Biology

Volumn 85, Issue 11, 2009, Pages 929-936

  Eke, Iris ^a   Hehlgans, Stephanie ^a   Cordes, Nils ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Integrin Linked Kinase; Ionising radiation; Tumour target

Indexed keywords

GROWTH FACTOR RECEPTOR; INTEGRIN; INTEGRIN LINKED KINASE;

CANCER CELL; CANCER CHEMOTHERAPY; CATALYSIS; CELL DEATH; CONTROLLED STUDY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; IONIZING RADIATION; KNOCKOUT GENE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; WILD TYPE;

ANIMALS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; SIGNAL TRANSDUCTION;

EID: 70449501169     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553000903232892     Document Type: Review

References (68)

1. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA. 2003. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. The Journal of Pathology 201:229-237.
2. Attwell S, Mills J, Troussard A, Wu C, Dedhar S. 2003. Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN. Molecular Biology of the Cell 14:4813-4825.
3. Attwell S, Roskelley C, Dedhar S. 2000. The integrinlinked kinase (ILK) suppresses anoikis. Oncogene 19:3811-3815.
4. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. 2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 354:567-578.
5. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. 2006. Emerging roles of pseudokinases. Trends in Cell Biology 16:443-452.
6. Bravou V, Klironomos G, Papadaki E, Stefanou D, Varakis J. 2003. Integrin-linked kinase (ILK) expression in human colon cancer. British Journal of Cancer 89:2340-2341.
7. Chen P, Shen WZ, Karnik P. 2004. Suppression of malignant growth of human breast cancer cells by ectopic expression of integrin-linked kinase. International Journal of Cancer 111:881-891.
8. Chiswell BP, Zhang R, Murphy JW, Boggon TJ, Calderwood DA. 2008. The structural basis of integrin-linked kinase-PINCH interactions. Proceedings of the National Academy of Sciences of the United States of America 105:20677-20682.
9. Chung DH, Lee JI, Kook MC, Kim JR, Kim SH, Choi EY, Park SH, Song HG. 1998. ILK (beta1-integrin-linked protein kinase): A novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour. Virchows Archiv 433:113-117.
10. Cordes N. 2004. Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Research 64:5683-5692.
11. Cordes N, Meineke V. 2003. Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlentherapie und Onkologie 179:337-344.
12. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, Martinka M, Li G. 2003. Increased expression of integrinlinked kinase is correlated with melanoma progression and poor patient survival. Clinical Cancer Research 9:4409-4414.
13. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. 1999. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658-1667.
14. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. 1998. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proceedings of the National Academy of Sciences of the United States of America 95:11211-11216.
15. Dong LQ, Liu F. 2005. PDK2: The missing piece in the receptor tyrosine kinase signaling pathway puzzle. American Journal of Physiology - Endocrinology and Metabolism 289:E187-196.
16. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. 2005. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clinical Cancer Research 11:3433-3438.
17. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. 2005. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24:3596-3605.
18. Eke I, Leonhardt F, Storch K, Hehlgans S, Cordes N. 2009. The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck. PLoS One 4:e6434.
19. Eke I, Sandfort V, Mischkus A, Baumann M, Cordes N. 2006. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiotherapy & Oncology 80:178-184.
20. Eke I, Sandfort V, Storch K, Baumann M, Roper B, Cordes N. 2007. Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. International Journal of Radiation Biology 83:793-802.
21. Goessler UR, Bugert P, Bieback K, Stern-Straeter J, Bran G, Hormann K, Riedel F. 2008. Integrin expression in stem cells from bone marrow and adipose tissue during chondrogenic differentiation. International Journal of Molecular Medicine 21:271-279.
22. Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW, Carter JH. 2001. Integrin-linked kinase expression increases with prostate tumor grade. Clinical Cancer Research 7:1987-1991.
23. Grashoff C, Aszodi A, Sakai T, Hunziker EB, Fassler R. 2003. Integrin-linked kinase regulates chondrocyte shape and proliferation. EMBO Reports 4:432-438.
24. Haase M, Gmach CC, Eke I, Hehlgans S, Baretton GB, Cordes N. 2008. Expression of integrin-linked kinase is increased in differentiated cells. The Journal of Histochemistry and Cytochemistry 56:819-829.
25. Hanks SK, Hunter T. 1995. Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. The FASEB Journal 9:576-596.
26. Hannigan G, Troussard AA, Dedhar S. 2005. Integrin-linked kinase: A cancer therapeutic target unique among its ILK. Nature Reviews Cancer 5:51-63.
27. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S. 1996. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379:91-96.
28. Hehlgans S, Eke I, Cordes N. 2007. An essential role of integrinlinked kinase in the cellular radiosensitivity of normal fibroblasts during the process of cell adhesion and spreading. International Journal of Radiation Biology 83:769-779.
29. Hehlgans S, Eke I, Deuse Y, Cordes N. 2008. Integrin-linked kinase: Dispensable for radiation survival of three-dimensionally cultured fibroblasts. Radiotherapy & Oncology 86:329-335.
30. Hess F, Estrugo D, Fischer A, Belka C, Cordes N. 2007. Integrinlinked kinase interacts with caspase-9 and -8 in an adhesiondependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene 26:1372-1384.
31. Hynes RO. 2002. Integrins: Didirectional, allosteric signaling machines. Cell 110:673-687.
32. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. 2005. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Molecular Cancer Therapeutics 4:1681-1688.
33. Kumar AS, Naruszewicz I,Wang P, Leung-Hagesteijn C, Hannigan GE. 2004. ILKAP regulates ILK signaling and inhibits anchorage-independent growth. Oncogene 23:3454-3461.
34. Legate KR, Montanez E, Kudlacek O, Fassler R. 2006. ILK, PINCH and parvin: the tIPP of integrin signalling. Nature Reviews Molecular Cell Biology 7:20-31.
35. Legate KR, Wickstrom SA, Fassler R. 2009. Genetic and cell biological analysis of integrin outside-in signaling. Genes & Development 23:397-418.
36. Leung-Hagesteijn C, Mahendra A, Naruszewicz I, Hannigan GE. 2001. Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin-linked kinase, ILK1. The EMBO Journal 20:2160-2170.
37. Liu J, Costello PC, Pham NA, Pintillie M, Jabali M, Sanghera J, Tsao MS, Johnston MR. 2006. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. Journal of Thoracic Oncology 1:771-779.
38. Lynch DK, Ellis CA, Edwards PA, Hiles ID. 1999. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 18:8024-8032.
39. Mackinnon AC, Qadota H, Norman KR, Moerman DG, Williams BD. 2002. C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes. Current Biology 12:787-797.
40. Makino K, Day CP, Wang SC, Li YM, Hung MC. 2004. Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. Oncogene 23:3883-3887.
41. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
42. Morimoto AM, Tomlinson MG, Nakatani K, Bolen JB, Roth RA, Herbst R. 2000. The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase activity. Oncogene 19:200-209.
43. Nikolopoulos SN, Turner CE. 2000. Actopaxin, a new focal adhesion protein that binds paxillin LD motifs and actin and regulates cell adhesion. The Journal of Cell Biology 151:1435-1448.
44. Nikolopoulos SN, Turner CE. 2001. Integrin-linked kinase (ILK) binding to paxillin LD1 motif regulates ILK localization to focal adhesions. The Journal of Biological Chemistry 276:23499-23505.
45. Obara S, Nakata M, Takeshima H, Katagiri H, Asano T, Oka Y, Maruyama I, Kuratsu J. 2004. Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398. Cancer Letters 208:115-122.
46. Papachristou DJ, Gkretsi V, Rao UN, Papachristou GI, Papaefthymiou OA, Basdra EK, Wu C, Papavassiliou AG. 2008. Expression of integrin-linked kinase and its binding partners in chondrosarcoma: Association with prognostic significance. European Journal of Cancer 44:2518-2525.
47. Pasquet JM, Noury M, Nurden AT. 2002. Evidence that the platelet integrin alphaIIb beta3 is regulated by the integrinlinked kinase, ILK, in a PI3-kinase dependent pathway. Thrombosis and Haemostasis 88:115-122.
48. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. 2000. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTENmutant prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 97:3207-3212.
49. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S. 2001. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrinlinked kinase: Critical roles for kinase activity and amino acids arginine 211 and serine 343. The Journal of Biological Chemistry 276:27462-27469.
50. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S. 2001. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1- mediated transcriptional activation. The Journal of Cell Biology 153:1161-1174.
51. Press MF, Lenz HJ. 2007. EGFR, HER2 and VEGF pathways: Validated targets for cancer treatment. Drugs 67:2045-2075.
52. Sakai T, Li S, Docheva D, Grashoff C, Sakai K, Kostka G, Braun A, Pfeifer A, Yurchenco PD, Fassler R. 2003. Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes & Development 17:926-940.
53. Sandfort V, Koch U, Cordes N. 2007. Cell adhesion-mediated radioresistance revisited. International Journal of Radiation Biology 83:727-732.
54. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current Biology 14:1296-1302.
55. Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD. 2001. Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. Journal of Cell Science 114:1125-1136.
56. Takanami I. 2005. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 5:1.
57. Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Herreros AG, Dedhar S. 2001. Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC7/7human colon carcinoma cells. Oncogene 20:133-140.
58. Turner CE, Glenney JR, Jr., Burridge K. 1990. Paxillin: A new vinculin-binding protein present in focal adhesions. The Journal of Cell Biology 111:1059-1068.
59. Vaynberg J, Fukuda T, Chen K, Vinogradova O, Velyvis A, Tu Y, Ng L, Wu C, Qin J. 2005. Structure of an ultraweak proteinprotein complex and its crucial role in regulation of cell morphology and motility. Molecular Cell 17:513-523.
60. Velyvis A, Vaynberg J, Yang Y, Vinogradova O, Zhang Y, Wu C, Qin J. 2003. Structural and functional insights into PINCH LIM4 domain-mediated integrin signaling. Nature Structural Biology 10:558-564.
61. White DE, Cardiff RD, Dedhar S, Muller WJ. 2001. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20:7064-7072.
62. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. 2007. Anaplastic thyroid carcinoma: Expression profile of targets for therapy offers new insights for disease treatment. Annals of Surgical Oncology 14:719-729.
63. Wood CK, Turner CE, Jackson P, Critchley DR. 1994. Characterisation of the paxillin-binding site and the C-terminal focal adhesion targeting sequence in vinculin. Journal of Cell Science 107 (Pt 2):709-717.
64. Yamaji S, Suzuki A, Kanamori H, Mishima W, Takabayashi M, Fujimaki K, Tomita N, Fujisawa S, Ohno S, Ishigatsubo Y. 2002. Possible role of ILK-affixin complex in integrincytoskeleton linkage during platelet aggregation. Biochemical and Biophysical Research Communications 297:1324-1331.
65. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. 2005. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabineinduced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Research 65:1497-1504.
66. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB, Myers JN. 2005. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Molecular Cancer Therapeutics 4:1146-1156.
67. Zervas CG, Brown NH. 2002. Integrin adhesion: When is a kinase a kinase? Current Biology 12:R350-351.
68. Zervas CG, Gregory SL, Brown NH. 2001. Drosophila integrinlinked kinase is required at sites of integrin adhesion to link the cytoskeleton to the plasma membrane. The Journal Cell Biology 152:1007-1018.